Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation

Molecular Cell

Volumn 52, Issue 2, 2013, Pages 161-172

  Shen, Che Hung ^a,b   Yuan, Ping ^a,b   Perez Lorenzo, Rolando ^b   Zhang, Yaqing ^c   Lee, SzeXian ^d   Ou, Yang ^b   Asara, John M ^d,e   Cantley, Lewis C ^f   Zheng, Bin ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KSR1 SCAFFOLDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN 14 3 3; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; ENERGY; ENZYME ACTIVATION; EPIDERMIS HYPERPLASIA; KERATINOCYTE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STRESS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; KERATINOCYTES; MAP KINASE SIGNALING SYSTEM; MICE; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS B-RAF; SERINE; SKIN;

EID: 84886244810     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2013.08.044     Document Type: Article

References (48)

1. Banko M.R., Allen J.J., Schaffer B.E., Wilker E.W., Tsou P., White J.L., Villén J., Wang B., Kim S.R., Sakamoto K., et al. Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol. Cell 2011, 44:878-892.
2. Brennan D.F., Dar A.C., Hertz N.T., Chao W.C.H., Burlingame A.L., Shokat K.M., Barford D. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 2011, 472:366-369.
3. Brummer T., Martin P., Herzog S., Misawa Y., Daly R.J., Reth M. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. Oncogene 2006, 25:6262-6276.
4. Callahan M.K., Rampal R., Harding J.J., Klimek V.M., Chung Y.R., Merghoub T., Wolchok J.D., Solit D.B., Rosen N., Abdel-Wahab O., et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N.Engl. J. Med. 2012, 367:2316-2321.
5. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N.Engl. J. Med. 2011, 364:2507-2516. BRIM-3 Study Group.
6. Costanzo-Garvey D.L., Pfluger P.T., Dougherty M.K., Stock J.L., Boehm M., Chaika O., Fernandez M.R., Fisher K., Kortum R.L., Hong E.-G., et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab. 2009, 10:366-378.
7. Downward J. Targeting RAF: trials and tribulations. Nat. Med. 2011, 17:286-288.
8. Esteve-Puig R., Canals F., Colomé N., Merlino G., Recio J.Á. Uncoupling of the LKB1-AMPKα energy sensor pathway by growth factors and oncogenic BRAF600E. PLoS ONE 2009, 4:e4771.
9. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N.Engl. J. Med. 2010, 363:809-819.
10. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
11. Green C.J., Macrae K., Fogarty S., Hardie D.G., Sakamoto K., Hundal H.S. Counter-modulation of fatty acid-induced pro-inflammatory nuclear factor κB signalling in rat skeletal muscle cells by AMP-activated protein kinase. Biochem. J. 2011, 435:463-474.
12. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., Turk B.E., Shaw R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
13. Hardie D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 2007, 8:774-785.
14. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13:251-262.
15. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., Ludlam M.J.C., Stokoe D., Gloor S.L., Vigers G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
16. Hauschild A., Grob J.-J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C.U., Miller W.H., Kaempgen E., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
17. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
18. Hu J., Yu H., Kornev A.P., Zhao J., Filbert E.L., Taylor S.S., Shaw A.S. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc. Natl. Acad. Sci. USA 2011, 108:6067-6072.
19. Huang X., Wullschleger S., Shpiro N., McGuire V.A., Sakamoto K., Woods Y.L., McBurnie W., Fleming S., Alessi D.R. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 2008, 412:211-221.
20. Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H. Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun. 2001, 287:562-567.
21. Inoki K., Zhu T., Guan K.-L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
22. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
23. Kim J., Yoon M.Y., Choi S.L., Kang I., Kim S.S., Kim Y.-S., Choi Y.K., Ha J. Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway. J.Biol. Chem. 2001, 276:19102-19110.
24. Liang J., Shao S.H., Xu Z.-X., Hennessy B., Ding Z., Larrea M., Kondo S., Dumont D.J., Gutterman J.U., Walker C.L., et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 2007, 9:218-224.
25. MacNicol M.C., Muslin A.J., MacNicol A.M. Disruption of the 14-3-3 binding site within the B-Raf kinase domain uncouples catalytic activity from PC12 cell differentiation. J.Biol. Chem. 2000, 275:3803-3809.
26. Martin M.J., Hayward R., Viros A., Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2012, 2:344-355.
27. McKay M.M., Ritt D.A., Morrison D.K. Signaling dynamics of the KSR1 scaffold complex. Proc. Natl. Acad. Sci. USA 2009, 106:11022-11027.
28. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13:1016-1023.
29. Müller J., Ory S., Copeland T., Piwnica-Worms H., Morrison D.K. C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Mol. Cell 2001, 8:983-993.
30. Noble C., Mercer K., Hussain J., Carragher L., Giblett S., Hayward R., Patterson C., Marais R., Pritchard C.A. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol. Cell 2008, 31:862-872.
31. Oberholzer P.A., Kee D., Dziunycz P., Sucker A., Kamsukom N., Jones R., Roden C., Chalk C.J., Ardlie K., Palescandolo E., et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J.Clin. Oncol. 2012, 30:316-321.
32. Osborne J.K., Zaganjor E., Cobb M.H. Signal control through Raf: in sickness and in health. Cell Res. 2012, 22:14-22.
33. Pérez-Lorenzo R., Zheng B. Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci. Rep. 2012, 32:25-33.
34. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
35. Rajakulendran T., Sahmi M., Lefrançois M., Sicheri F., Therrien M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009, 461:542-545.
36. Ribas A., Flaherty K.T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 2011, 8:426-433.
37. Ritt D.A., Monson D.M., Specht S.I., Morrison D.K. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell. Biol. 2010, 30:806-819.
38. Robert C., Arnault J.-P., Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr. Opin. Oncol. 2011, 23:177-182.
39. Roskoski R. RAF protein-serine/threonine kinases: structure and regulation. Biochem. Biophys. Res. Commun. 2010, 399:313-317.
40. Rushworth L.K., Hindley A.D., O'Neill E., Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 2006, 26:2262-2272.
41. Scott J.W., Norman D.G., Hawley S.A., Kontogiannis L., Hardie D.G. Protein kinase substrate recognition studied using the recombinant catalytic domain of AMP-activated protein kinase and a model substrate. J.Mol. Biol. 2002, 317:309-323.
42. Shackelford D.B., Abt E., Gerken L., Vasquez D.S., Seki A., Leblanc M., Wei L., Fishbein M.C., Czernin J., Mischel P.S., Shaw R.J. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013, 23:143-158.
43. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-99.
44. Sprenkle A.B., Davies S.P., Carling D., Hardie D.G., Sturgill T.W. Identification of Raf-1 Ser621 kinase activity from NIH 3T3 cells as AMP-activated protein kinase. FEBS Lett. 1997, 403:254-258.
45. Steinberg G.R., Kemp B.E. AMPK in health and disease. Physiol. Rev. 2009, 89:1025-1078.
46. Su F., Viros A., Milagre C., Trunzer K., Bollag G., Spleiss O., Reis-Filho J.S., Kong X., Koya R.C., Flaherty K.T., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N.Engl. J. Med. 2012, 366:207-215.
47. Udell C.M., Rajakulendran T., Sicheri F., Therrien M. Mechanistic principles of RAF kinase signaling. Cell. Mol. Life Sci. 2011, 68:553-565.
48. Zheng B., Jeong J.H., Asara J.M., Yuan Y.-Y., Granter S.R., Chin L., Cantley L.C. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 2009, 33:237-247.